Latest News

Cambridge Rare Disease Network Logo
05 Jan 2022
Charity of the Year 2022 Announced

The Anglonordic Life Science Conference has announced Cambridge Rare Disease Network (CRDN) as their Charity of the Year for 2022. Conference delegates will have the opportunity to meet CRDN during the conference programme including panel discussions, 1:1 networking and the exhibition.

CRDN is a platform for change. It is the infrastructure that unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare diseases. By sharing knowledge and experience, and working together, the journey towards better diagnosis, treatment and support for patients and their families is smoother and more certain.

Cambridge Rare Disease Network is absolutely delighted to be selected as the Anglonordic Life Science Charity of the Year for 2022! It is a privilege to be given this opportunity to raise our profile and the challenge of rare diseases amongst key industry leaders and companies with a shared passion for innovation in drug discovery and technology." Jo Balfour, Managing Director, CRDN
Read more
08 December 2021
Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures.

The new investment of € 600 million allocated to M Ventures will be deployed over the next five years. This is the third increase in financial commitment announced by Merck KGaA, Darmstadt, Germany, since the creation of M Ventures in 2009. The increase will be used to further grow both the number and size of investments.

“Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. 

Meet the M Ventures team during the programme and 1:1 networking at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

Read more
01 December 2021
BioPartner launches start-up and loyalty membership tiers at discounted rates

Qualifying startups can now get BioPartner membership for only £400 +vat when meeting the following criteria:

  • Company/Academic group Created in the past two years
  • Has fewer than five employees
  • Pre-revenue
  • Developing new therapeutic products, technology platforms, or digital medicine technologies
  • CRO and Service companies welcome 

New benefits also include 50% off Anglonordic Life Science Conference fees including sponsorship & exhibitor packages - to enable start up members to meet and pitch to investors, and suppliers to exhibit at a low cost rate.

BioPartner are a co-organiser of the Anglonordic Life Science Conference. Meeting the team during 1:1 networking on Thursday 5th May, County Hall, London.

Claim discount
01 September 2021
McDermott Will & Emery


McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, their purpose-built team of thought leaders is united by a passion for their work. Their team can meet the legal needs of life sciences companies at every stage of development. For decades, they have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of their team.

Meet the McDermott Will & Emery team during the programme and 1:1 networking at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

Read more
01 July 2021
Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms

Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio company. With the addition of GeneWerk’s unique capabilities in vector safety, characterization, and functionality analysis, PPS will complement its current analytical testing offering in protein characterization identity, purity, potency and capsid loading to become a full-service partner in gene therapy testing for the biopharmaceutical industry.

Today’s announced merger creates a leading partner for the worldwide biopharmaceutical industry to benefit from the most advanced, integrated set of analytical services capabilities in biologic development, especially in gene and cell therapy-related testing, from early development through drug approval to commercialization. The combined organization will have more than 175 employees across four sites in Europe and North America.

Meet the Protagen Protein Services team during 1:1 networking and at their Exhibition stand at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

Read more
30 June 2021
Dame Kate Bingham’s Keynote from the 17th Anglonordic Life Science Conference

At the 17th Anglonordic Life Science conference this year Kate Bingham discussed the actions of the VTF, how parties were brought together, and how they tackled the procurement, manufacturing, and distribution challenges they were faced with in what was a triumph of science and global collaboration.

Key takeaways
Time is of the essence – it doesn’t have to be perfect! The previous fastest development of a vaccine from recognition of a disease (measles) to a licensed vaccine in the US was 10 years and there was a clear need to speed up development of COVID-19 vaccines. The Prime Minister stressed that “time is of the essence, it doesn’t have to be perfect!” and set three goals:

  • Secure effective COVID-19 vaccines for the UK
  • Ensure successful vaccines are distributed internationally to all who need it
  • Put plans in place to be better prepared next time around

Read more
30 June 2021
If I Knew Then, What I Know Now

Mike Ward, Global Head of Thought Leadership at Decision Resources Group, part of Clarivate, chaired a panel of top industry executives at the Anglonordic Life Sciences Conference: Renee Aguiar-Lucander, CEO Calliditas Therapeutics, Steven Powell, CEO eTheRNA immunotherapies and Roel Bulthuis, Managing Partner at INKEF Capital, shared key decisions that shaped the fate of their various enterprises. What would they do differently and what would they not hesitate to do again? We share top takeaways from this insightful discussion.

IPO your business

  • Floating your enterprise is a marathon, not a sprint. It requires building relationships with investors, auditors, lawyers while building the organization internally. You need to have these connections and ‘boots’ on the ground and it takes time to build these relationships.
  • Whether or not to IPO in US vs Europe should really be determined by the company’s capital needs, the size and maturity of your business and also your existing shareholder base – the need for crossover investors is important. The ultimate goal is to align the business’s capital allocation strategy with its operational strategy: where are your potential competitors and peer group; where is the addressable market and will you need to set up a commercial organization based in the US?

Read more
02 June 2021
Takeaways from EU VCs Panel Discussion

Amber Tong, Senior Editor at Endpoints, chaired a fantastic panel of Europe’s leading VC investors at the Anglonordic conference. The panel included: Hakan Goker – M Ventures; Debbie Harland – SR One; Nanna Lüneborg – Novo Ventures: and Stephan Christgau – EIR Ventures. We have summarised the top takeaways below.

How has the pandemic impacted your business and what is the new normal?

  • Despite the pandemic, venture firms have successfully closed funds, exited investments (both through IPOs and M&A) and invested in new and exciting companies.
  • For investors who spend a significant time travelling, it has been very efficient and productive to have meetings online. Additionally, it has been tricky, but not impossible, to hire people remotely into a team or a portfolio company.
  • Venture Capital is a people driven business relying heavily on relationship building. However, you can witness other, more personal aspects of a colleague’s life with the sudden appearance of a child or a pet to liven up an online meeting – and these instances can help forge close relationships.
  • Investors miss face to face meetings, dinners and spontaneous discussions, and for future expect a hybrid of virtual and in-person encounters.

Read more
26 May 2021
Building Your Board - PIR International Panel Discussion

PIR International recently hosted a panel of Biotech industry experts on the topic of ‘Building your Board’ during the 17th Anglonordic life science conference, doing a deep dive on all things necessary to set-up a successful Board for all stages of growth.

As anticipated, it was expertly hosted by Maureen Coleman. Maureen was joined by a superb panel of Eva-Lotta Allen, Edwin Moses, Patrick Vink and Melanie Lee. The discussion was tremendously insightful, providing healthy debate and conversation around all aspects of Board composition, diversity, structure, culture and much more.

The utilisation of independent board members, why and when to engage them, and indeed how many does a Board need to ensure a balanced external board level input and yet not to overpopulate the Board, was just one of many chapters of insight from the panel.

Watch again